
-
Corvus NasdaqGM:CRVS Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Location: 901 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.corvuspharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
250M
Cash
44.21M
Avg Qtr Burn
-7.133M
Short % of Float
11.45%
Insider Ownership
3.80%
Institutional Own.
49.07%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Soquelitinib (CPI-818) Details Cancer, Blood cancer, Peripheral T-cell Lymphomas | Phase 3 Data readout | |
Soquelitinib Details Autoimmune Lymphoproliferative Syndrome | Phase 2 Data readout | |
Mupadolimab (CPI-006) Details Cancer, Lung cancer, Renal cell carcinoma, Non-small cell lung carcinoma | Phase 2 Update | |
Soquelitinib (CPI-818) Details Cancer, Renal cell carcinoma (renal cell cancer) | Phase 2 Initiation | |
Ciforadenant +/- ipilimumab and nivolumab Details Cancer, 1L metastatic renal cell carcinoma (renal cell cancer) | Phase 1/2 Data readout | |
Mupadolimab + pembrolizumab Details Cancer, Head and neck cancer, Non-small cell lung carcinoma | Phase 1 Data readout | |
Soquelitinib (CPI-818) Details Atopic dermatitis | Phase 1 Data readout | |
Mupadolimab (CPI-0060) Details COVID-19 | Failed Discontinued |